There has been an explosion in the number of cancer therapeutics and clinical trials in the recent past, owing to our ability to better define the molecular targets of different cancers using cutting-edge technologies. Unlike in the past, data from early-stage clinical trials are getting more attention lately because the efficacy of a therapeutic, traditionally evaluated in later-phase trials, is often becoming evident earlier in the course of clinical testing.Read More
After three decades of failed efforts to target the elusive KRAS and its family members NRAS and HRAS, proto-oncogenes altered in about a third of cancers, encouraging data emerging from clinical trials and preclinical studies suggest KRAS could finally be dethroned from the “undruggable” category.Read More
Providing a forum for innovative cancer researchers around the world, Singapore will hold its 11th Frontiers in Cancer Science (FCS) conference from November 4-6 at Academia at SingHealth.
The conference is jointly organized by the Cancer Science Institute of Singapore, Duke-NUS Medical School, Genome Institute of Singapore, Institute of Molecular and Cell Biology, Lee Kong Chian School of Medicine, National Cancer Centre Singapore, and National University Cancer Institute, Singapore.Read More
The women bustle around a warm, colorful kitchen, making tamales for an upcoming family party. A woman in her 20s has received the distressing news that she has tested positive for the human papillomavirus (HPV). She’s upset and angry, but also resolved to do everything she can to prevent the virus from developing into cervical cancer.Read More
Since its inception in 1993, the American Association of Cancer Research (AACR) Grants Program, in partnership with other nonprofit organizations, foundations, and pharmaceutical companies, has funded groundbreaking basic, translational, and clinical cancer research. In 2019 alone, the AACR awarded more than $12.5 million in grants to support innovative and impactful cancer research projects.
The AACR Grants Program supports researchers at all career levels by awarding fellowships, career development awards, independent investigator awards, team science awards, and its flagship NextGen Grants for Transformative Cancer Research.Read More
The 12th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved wrapped up Monday in San Francisco. This year marked record attendance for the conference, as well as a record number of abstracts that helped shape a dynamic, diverse program.
The meeting reinforced the central dilemma of cancer health disparities: While advances in cancer research have improved outcomes for many Americans, underserved and underrepresented groups have not benefited equally.Read More
In the effort to include more diverse patient populations in clinical trials, good intentions can easily go awry.
Panelists in the “Addressing Advocacy at the Bench: Implementing Change” session held Sunday …
The injustices come in many ways.
A transgender woman is admitted to the hospital for cancer treatment. Her physicians decide to wean her from the hormones that have enabled her to …
The 12th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved kicked off Friday evening in San Francisco with a passionate call to fight cancer disparities on every front, from socioeconomic to biological.
“Everyone in this room is united in our goal to eliminate cancer health disparities,” said conference cochair Phyllis Pettit Nassi, MSW, manager of Special Populations and Native American Outreach at Huntsman Cancer Institute in Salt Lake City. “Medical research powers our ability to treat our patients. Conferences such as this, where we unite as a community, fuel hope that we can improve the lives of our patients.”Read More
In recent decades, the cancer research community has made great strides by bringing new, targeted, safer, and longer-lasting treatments to patients dealing with a variety of cancers. While this achievement is truly remarkable and laudable, a glaring fact is that these groundbreaking advances have not translated into progress for everyone.Read More